The pharmaceutical industry is coming out with all these new glutamine targeting drugs. The problem is a lot of them don't work effectively that we use dirty drug,dirty drug in the pharmaceutical industry because there's no specificity to it. I would say the patients need to go to their Congress for crying out loud. Get the doctors, oh, I want to give my patient 60 oxy nor lucine, but I can't get it. Where am I going to get it? And the answer is why they should be available.
Thomas Seyfried, PhD is a preeminent cancer expert and professor in the department of biology at Boston College. He received a PhD in 1976 in genetics and neurochemistry from the University of Illinois at Urbana-Champaign, followed by a postdoctoral degree from Yale University in the field of neurochemistry and genetics.
Become a Genius Life Premium Member and get ad-free episodes of the show, a monthly Ask Me Anything (AMA), and more! Learn more: http://thegeniuslife.com